结合用于慢性淋巴细胞白血病的易布鲁替尼和venetoclax:实践中的协同作用
Natalia Timofeeva1, Nitin Jain2, Varsha Gandhi1,2
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
易布鲁替尼和维尼托克拉克斯的组合显示出对慢性淋巴细胞白血病 (CLL) 治疗的显著前景,改善生存率并实现不可检测的最小残留疾病 (MRD). 这种口服治疗方案为患者提供了一种方便的,时间有限的方法.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 治疗已经随着向治疗而发展.
- 易布鲁替尼和venetoclax的组合显示出临床前协同作用的抗瘤效应.
- 需要方便,具有成本效益和时间限制的CLL治疗选择.
研究的目的:
- 审查ibrutinib和venetoclax组合在CLL中的临床疗效和安全性.
- 检查研究人员发起的和多中心临床试验的结果.
- 探索MRD驱动的与固定持续时间的治疗策略.
主要方法:
- 对研究人员发起的和多中心临床试验数据的审查.
- 对无进展生存率和整体生存率的分析.
- 评估安全概况和遗传变量的影响,如染色体17p删除.
主要成果:
- 治疗先前和复发/耐药性CLL患者的无进展和整体存活率显著改善.
- 实现了不可检测的最小残留疾病 (MRD) 的高率.
- 在临床试验更新中观察到的持久反应.
结论:
- 易布鲁替尼和维尼托克拉克斯的组合是一种高度有效和持久的CLL治疗方法.
- 这种方案提供了一个方便的,时间有限的口服治疗选择.
- 进一步的研究可能会将这种组合扩展到其他B细胞恶性瘤,并完善未来的CLL治疗策略.
更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
